Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Small Cell Lung Carcinoma 13Burkitt Lymphoma 7Lung Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Carcinoma, Non-Small-Cell Lung 4Sarcoma, Ewing 3Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Teratoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2HIV Infections 2Ganglioneuroblastoma 2Central Nervous System Neoplasms 2Carcinoma, Embryonal 2Wilms Tumor 1Stage I Mixed Cell Type Kidney Wilms Tumor 1

Interventions

Dexamethasone 60Lenalidomide 33daratumumab 32pomalidomide 30Bortezomib 28carfilzomib 22Specimen Handling 21Biopsy 20Cyclophosphamide 19Magnetic Resonance Spectroscopy 16Calcium Dobesilate 16fludarabine 12isatuximab 11dexamethasone acetate 11dexamethasone 21-phosphate 11belantamab mafodotin 11auricularum 11talquetamab 9iberdomide 8tocilizumab 7selinexor 7elotuzumab 6trametinib 4pembrolizumab 4nirogacestat 4fludarabine phosphate 4X-Rays 4Sirolimus 4Melphalan 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Etoposide × 30 days × Clear all
NCT00734877 2026-05-22

TT4B

University of Arkansas

Phase 3 Active not recruiting
382 enrolled
Plasma cell

Multiple Myeloma

NCT00869232 2026-05-22

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

University of Arkansas

Phase 2 Active not recruiting
90 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡